Clinical Trials
7 trialsNCT05067283 2026-05-26
KANDLELIT-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT07415031 2026-05-15
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Phase 2 Recruiting
NCT06227377 2026-04-27
QTX3034 in Patients With KRAS G12D Mutation
Quanta Therapeutics
Phase 1 Recruiting
NCT07204340 2026-04-21
TLN-372 in Advanced KRAS Mutant Solid Tumors
Treeline Biosciences, Inc.
Phase 1 Recruiting
NCT05203172 2026-04-07
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Pfizer
Phase 4 Recruiting
NCT02215720 2026-03-20
TORERO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT06585488 2026-03-18
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeOne Medicines
Phase 1 Recruiting